{
    "nctId": "NCT05183126",
    "briefTitle": "Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Breast Cancer",
    "officialTitle": "Phase IV Single-arm Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 22,
    "primaryOutcomeMeasure": "Maximum concentration (Cmax) of paclitaxel plasma",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Stage 1-3 breast cancer\n* Planned neoadjuvant, adjuvant, or curative intent paclitaxel 80 mg/m\\^2, 1-hour infusion (note: combination treatment, e.g., trastuzumab, pertuzumab, carboplatin, or pembrolizumab, and prior treatment, e.g., doxorubicin and cyclophosphamide, are allowable.\n* Evaluable computed tomography (CT) scan, e.g., scan of the chest, abdomen, or pelvis for any indication within 1 year.\n* Adequate organ function based on paclitaxel label.\n* Ability to understand and the willingness to sign a written informed consent.\n\nExclusion Criteria:\n\n* Concomitant administration of any moderate or strong inducer or inhibitor of CYP2C8, including rifampin or clopidogrel.\n* History of hypersensitivity reaction to paclitaxel or any components of paclitaxel (e.g., Cremophor EL) that precludes continued treatment with standard dose and infusion length\n* Pregnant or nursing",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}